



Norgine announces the first launch of Oramorph

15 March 2005

As from, March 15th, the Norgine sales force in Germany has begun selling ORAMORPH®, a range of oral liquid morphine products including a novel unit dose vial presentation, for the treatment of moderate to severe pain associated with cancer. This is the first launch by a Norgine company since the deal to market the product in 10 European countries was concluded with Molteni Farmaceutici.

Commenting on the launch Norgine COO, Peter Martin stated “This is an important day for Norgine as not only is it a new product launch but it also represents our first entry within the area of pain management. We are confident that Oramorph will contribute significantly to the future growth of Norgine. We are also grateful to the help of our partner, Molteni in achieving a timely first launch”.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for almost 100 years and has a presence in all the major European markets. The company employs 900 people, of which 350 are in sales and marketing.

Norgine’s current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy. Fivasa® for the treatment of inflammatory bowel disease and Oramorph® for the treatment of moderate to severe pain.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA in 2005.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine’s website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk